Science & Co Review: What the Subscription Terms Explain—and What They Leave Open

The most important number in Science & Co’s advertising is not necessarily the amount a new customer would pay at checkout. Compounded semaglutide injection starts at $59 a month, and compounded tirzepatide injection starts at $99 a month—but both minimums are tied to 12-month plans. Meanwhile, the company advertises no lock-in and cancellation without a fee. Those statements are not automatically incompatible. The missing piece is a clear explanation of the initial charge and what happens financially when someone leaves before completing the advertised plan period.

This documentary review examines that gap alongside the practical terms of enrollment, prescribing, pharmacy fulfillment and ongoing support. Public pages consulted October 19, 2026, describe Science & Co as a technology and administrative platform connecting patients with independent clinicians and pharmacies, rather than the organization directly delivering every service. Its documentation provides useful detail about cancellation notice, included services and cash payment. It is less complete about refunds, specific fulfillment partners and the economics of early cancellation. For a prospective patient, those are questions to resolve before authorizing recurring charges.

At a glance

Advertised starting prices: Compounded semaglutide injection starts at $59/month and compounded tirzepatide injection at $99/month, each on a 12-month plan; the initial collection amount is not established.
Sources: [11] [12]
Cancellation deadline: Pause or cancel at least 72 hours before the next scheduled processing date, through the account or support email. Cancellation does not reverse orders already prescribed, dispensed or shipped.
Sources: [11] [6]
Who provides care: Science and Co, Inc. identifies itself as a platform; independent professional entities provide healthcare, and independent pharmacies dispense prescriptions.
Sources: [9]
Payment restrictions: The service is cash-pay. Its terms prohibit seeking reimbursement from federal, state or private healthcare payors for services or products obtained through the platform.
Sources: [6] [9]
Access boundaries: The terms advertise availability in all 50 states and Washington, DC, for individuals located in the United States, with access restricted to adults 18 and older.
Sources: [9]

The cancellation promise needs a financial explanation

Science & Co’s product page says there is “no lock in and no cancellation fee.” It also says cancellation stops future orders without reversing an order that has already been prescribed, dispensed or shipped. That distinction matters: ending a subscription and recovering money for an existing order are different actions. The public wording supports an ability to stop future processing, subject to notice. It does not establish a general right to a refund or identify every stage at which payment becomes nonrefundable.

The unresolved issue is the relationship between that flexibility and prices advertised on 12-month plans. The consulted documentation does not establish whether these plans require advance payment, what amount is collected initially, or whether ending early changes the price of treatment already received. A 12-month price label alone does not establish a minimum commitment, shipment quantity or mandatory prepayment. Equally, “no cancellation fee” does not answer whether other price adjustments could apply.

Before enrolling, ask for a written example showing the amount due today, the next charge date and the financial outcome of canceling after an early shipment. The answer should identify any balance, repricing or refund calculation—or explicitly confirm that none applies. Our guide to monthly prices and billing commitments explains why those are separate questions. Here, resolving them would turn an attractive price headline into a usable agreement.

Sources: [11] [12]

What the published prices actually cover

The $59 starting price applies to compounded semaglutide injection on a 12-month plan; the $99 starting price applies to compounded tirzepatide injection on that plan length. Both pages advertise the same price across doses, no monthly membership charge and free shipping. Semaglutide’s headline also shows a $149 reference price and an advertised 60% saving; tirzepatide shows $199 and an advertised 50% saving. Those reference figures do not, by themselves, establish the price of a separate month-to-month option.

A personalized GLP-1/GIP-1 injection page also advertises plans starting at $59 monthly on a 12-month plan, but its quoted heading does not identify the active ingredient. Separately, the homepage promotes 20% off the first month and a free online provider evaluation. The consulted pages do not explain whether that promotion combines with the 12-month minimums. They also do not publish concrete prices for the branded products reviewed here.

The terms say a subscription’s total price can combine the pharmacy’s medication charge, the professional entity’s clinical charge and platform-access fees. That is compatible with advertising no separate monthly membership, but it means the payment supports several participants. Published plan inclusions are broad; laboratory costs, if testing is requested, remain unclear. Ask for an itemized quote that separates included services from possible additional charges rather than assuming every future need is covered.

Published offers and the contract questions they leave open
Offer	Documented condition	Clarify before paying
Compounded semaglutide injection	Starts at $59/month on a 12-month plan; same price across doses	Initial charge and early-cancellation accounting
Compounded tirzepatide injection	Starts at $99/month on a 12-month plan; same price across doses	Billing interval and any advance collection
Personalized GLP-1/GIP-1 injection	Starts at $59/month on a 12-month plan	Exact active ingredient and formulation
First-month promotion	20% off first month and free online provider evaluation	Eligibility and whether discounts combine
Branded products	Advertised in the catalog; concrete prices not established	Product-specific price and included services

Sources: [11] [12] [13] [3] [9]

Enrollment connects several organizations

The terms identify the operator as Science and Co, Inc., a Delaware corporation. They explicitly state that Science & Co is not a medical-services provider and does not dispense medication. Instead, independent licensed clinicians and professional entities provide healthcare, while pharmacies handle prescription fulfillment and dispensing. This is a meaningful allocation of responsibility: a platform billing question, a treatment decision and a dispensing problem may need different people, even when the patient encounters them through one website.

The terms advertise access throughout all 50 states and the District of Columbia, only for people located in the United States. Users must be at least 18. Those are service-access conditions, not a complete statement of clinical eligibility. The consulted documentation does not identify the professional entity, individual prescriber or dispensing pharmacy that would serve a particular patient. Nor does it establish complete BMI criteria, medical exclusions or a standard laboratory-testing requirement.

Before payment, request the names and contact routes for the organizations responsible for your consultation and medication. This is especially useful if you expect to move, use an outside pharmacy or need records later. A map of platform, clinician and pharmacy responsibilities can help organize those questions. Science & Co’s role separation is clearly stated; the patient-specific identities and handoffs still need confirmation.

Sources: [9]

An online assessment is not a prescription guarantee

Science & Co describes an initial online questionnaire taking about five minutes, with no commitment at that stage. The displayed intake asks about previous GLP-1 use, type 2 diabetes, thyroid history, and pregnancy or nursing. These questions show some of the information collected; they do not establish that every person selecting a particular answer is eligible or excluded. The terms make the decisive boundary explicit: receiving a prescription requires a completed consultation, a clinician’s determination that the product is appropriate and an issued prescription.

The product page says most clinical reviews are completed within 24–48 hours. That is an advertised review window, not a promise that medication will arrive within two days. Science & Co also says prescriptions come from a provider licensed in the patient’s state and nothing is dispensed without that provider’s approval. These are provider representations, not independent verification of a particular clinician’s license or a guarantee that the assessment will result in treatment.

The catalog spans compounded semaglutide and tirzepatide injections, a personalized GLP-1/GIP-1 injection, branded Zepbound and Wegovy injections, and advertised Wegovy semaglutide and Foundayo orforglipron tablets. The Microdose offering is not confirmed available: its specific page says “Coming Soon,” despite conflicting catalog labeling. NAD+ and sermorelin injections also appear under longevity. Those additional listings describe catalog breadth, not evidence that they are included in a GLP-1 subscription.

Sources: [11] [12] [13] [4] [7] [8] [10] [5] [3] [9]

Recurring billing and the 72-hour processing boundary

For subscription products, the terms authorize automatic charges at the recurring intervals disclosed during checkout until cancellation. The public starting price therefore is not enough to establish the billing schedule: the checkout disclosure matters. A monthly price expression, a recurring charge interval and the duration attached to a promotional plan can be three different things. The consulted documentation does not settle those details for the 12-month offers, so retain the checkout schedule and the version of the agreement presented when enrolling.

The operational deadline is the next scheduled processing date. Science & Co says customers can pause or cancel from their account, or email support@science.co, at least 72 hours before that date. Do not substitute an expected delivery date or the day a bank charge appears. The company’s wording makes processing the reference point, and a prescription may already have progressed before a package ships. The documentation does not explain whether a pause changes promotional pricing or how long a pause may last.

A useful cancellation request should identify the subscription, request confirmation that future processing has stopped and ask whether any current order remains active. Keep the request and response. Our guide to cancellation notice and order status explains this distinction without assuming that cancellation produces a refund. Science & Co’s account and email routes are useful documented options, but neither removes the notice requirement or reverses an already prescribed, dispensed or shipped order.

Sources: [9] [11] [6]

Pharmacy choice does not resolve delivery and refund questions

The terms allow an issued prescription to be filled through an accessible pharmacy or sent to a pharmacy the patient chooses. That is a useful access provision, but it does not explain how outside fulfillment changes the subscription price, shipping benefits or clinical-service charges. Science & Co says it works with state-licensed U.S. compounding pharmacies, that every batch undergoes third-party purity and potency testing, and that patients can request a Certificate of Analysis. Those are company claims; the consulted pages do not name the pharmacy for an individual order.

The product page advertises free home delivery on a monthly schedule, without specifying carriers or firm preparation and transit windows. The terms warn that medication may not arrive in child-resistant packaging. A complete shipping, returns and replacement policy was not established in this review because the Shipping & Returns content was not consulted. Consequently, the documentation reviewed here cannot answer who bears the cost of a lost, damaged or temperature-compromised shipment, or when a refund would be available.

FDA advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy. That safety instruction should not be confused with a promise of free replacement. Before ordering, ask which organization handles delivery problems, what evidence it requests and whether replacement or reimbursement is offered. The broader distinction between cancellation and refund boundaries is particularly relevant when an order is already in pharmacy processing.

Sources: [11] [9] [1]

Cash payment has broader limits than nonacceptance of insurance

Science & Co’s FAQ calls the service cash-pay and says it does not submit claims to insurance, Medicare or Medicaid. Its terms go further: neither the patient nor the participating platform, clinicians, professional entities or pharmacies may seek or receive reimbursement from federal, state or private healthcare payor programs for services or products provided through the service. This is not merely a statement that the company will not handle paperwork. A prospective patient should understand that contractual restriction before planning to seek reimbursement independently.

The FAQ separately describes treatment as generally HSA- and FSA-eligible and offers itemized receipts. That is the provider’s description, not a determination about an individual account or expense. Request the receipt details and confirm requirements with the account administrator rather than treating the website statement as a reimbursement guarantee. The consulted pages also do not establish branded-drug prices, so someone comparing a compounded subscription with a branded option needs a product-specific written quote, not just the catalog’s cash-pay language.

Sources: [6] [9]

Ongoing care promises deserve their own confirmation

The advertised plan includes an assessment reviewed by a licensed clinician, secure messaging, scheduled check-ins, clinically appropriate treatment adjustments, supplies, shipping and ongoing monitoring. The FAQ says the same provider stays with the patient month to month. However, monthly check-in language and an illustrative interface describing weekly check-ins during the first eight weeks do not establish one consistent contractual schedule. Ask what contact is scheduled, who conducts it and what happens if the usual clinician is unavailable.

Science & Co advertises 24/7 support as the ability to message the care team at any time; it does not publish a guaranteed response time in the consulted material. The contact page identifies account messaging as the fastest member route. Email support@science.co and telephone 1 (844) 587-5747 are also published. The website is not for emergencies and directs users to 911 or an emergency department. Around-the-clock message submission should not be read as immediate clinical availability.

Product status remains separate from service quality. Science & Co acknowledges that compounded preparations are not FDA approved; FDA recommends them when an individual’s medical needs cannot be met by an approved drug. Nonapproval alone does not establish clinical inequivalence. Claims on the branded tablet pages about manufacturer, sealed dispensing and FDA approval are provider statements, not independent verification here, and any product approval would not approve the platform. Contract clarity can improve purchasing decisions without proving clinical outcomes.

Sources: [11] [6] [8] [10] [2] [9] [1]

Questions & answers

Will Science & Co charge only $59 when I enroll?

That is not established. The $59 figure is a starting monthly price for compounded semaglutide injection on a 12-month plan, not a confirmed checkout charge. The consulted documentation does not say whether that plan requires advance collection or another payment arrangement. Ask for the exact amount due initially, the recurring interval and the cancellation accounting before authorizing payment.

Sources: [11] [9]

How do I stop a Science & Co subscription?

The published routes are your account or an email to support@science.co, with notice at least 72 hours before the next processing date. Ask for confirmation of the effective stop date and any active order. The company says cancellation stops future orders but does not reverse one already prescribed, dispensed or shipped; it is not a blanket refund promise.

Sources: [11] [6]

Can I use my own pharmacy?

The terms permit a prescription to be sent to a pharmacy you choose if a clinician issues it. They do not explain whether doing so reduces the subscription charge, changes delivery benefits or creates separate pharmacy expenses. Confirm those financial details and the destination pharmacy’s ability to fill the particular prescription before relying on this option.

Sources: [9]

Can I submit a Science & Co receipt to insurance myself?

The terms prohibit patients and participating organizations from seeking or receiving reimbursement from public or private healthcare payor programs for products or services obtained through the platform. That is broader than simply declining to submit claims. The FAQ separately offers itemized receipts and describes treatment as generally HSA/FSA-eligible; that statement should be checked against your account administrator’s requirements.

Sources: [9] [6]

Does 24/7 support mean a clinician will respond immediately?

No immediate-response guarantee is established. Science & Co says patients can message their care team any time, and its contact page recommends account messaging as the fastest member route. The documentation does not specify a guaranteed response interval. It also explicitly excludes medical emergencies, directing people to call 911 or go to an emergency department.

Sources: [11] [2]

Does the consultation guarantee medication within 48 hours?

No. Science & Co says most clinical reviews take 24–48 hours; that is neither a prescription guarantee nor a delivery deadline. The terms require a completed consultation, an appropriateness determination and an issued prescription. Free monthly shipping is advertised, but the consulted material does not establish specific preparation or transit times for an individual order.

Sources: [11] [9]

Our assessment

Science & Co documents several useful contractual details: a defined cancellation notice period, account and email cancellation routes, a separation of platform and clinical responsibilities, pharmacy choice, and substantial advertised plan inclusions. Its public pricing also identifies the 12-month condition behind the lowest compounded-injection rates rather than leaving that condition entirely unstated. The central weakness is the missing financial bridge between those rates and the no-lock-in promise. Before subscribing, obtain written confirmation of the initial payment, recurring schedule, early-cancellation consequences and treatment of orders already in progress. Product-specific pharmacy identities, delivery remedies and a complete refund policy would also improve decision readiness. The documentation supports reviewing Science & Co as an advertised GLP-1 access platform, but not treating its lowest monthly figures as confirmed month-to-month checkout prices or its cancellation language as a money-back guarantee.

Visit Science & Co’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Science & Co Review: What the Subscription Terms Explain—and What They Leave Open

At a glance

01The cancellation promise needs a financial explanation

02What the published prices actually cover

03Enrollment connects several organizations

04An online assessment is not a prescription guarantee

05Recurring billing and the 72-hour processing boundary

06Pharmacy choice does not resolve delivery and refund questions

07Cash payment has broader limits than nonacceptance of insurance

08Ongoing care promises deserve their own confirmation